10 stocks to watch on Friday, Nov 28: Tata Power, Tata Elxsi, Emcure Pharma, GMR Airports, Wipro and more – Markets
Mahindra Holidays to Launch Signature Resorts by FY27
Mahindra Holidays & Resorts India expects to open the first property under its luxury leisure hospitality brand ‘Mahindra Signature Resorts’ in the later part of FY27, according to its Managing Director & CEO Manoj Bhat. The company, which last week announced plans to enter the luxury leisure hospitality segment, has earmarked an investment of Rs 1,000 crore for the same.
Tata Elxsi partners with Druid Software
Tata Elxsi has announced a strategic partnership with Druid Software, a global leader in cellular network technology. This collaboration brings together end-to-end expertise in 5G networks, offering enterprises a powerful ecosystem to accelerate digital transformation through xG-Force, Tata Elxsi’s Lab-as-a-Service (LaaS) platform.
GMR Airports: Rs 750 Cr Loan for Delhi Cargo City
Mahindra & Mahindra EV Sales Target
Mahindra & Mahindra plans to sell around 7,000 electric vehicle units by the end of this fiscal. The Mumbai-based auto maker currently sells between 4,000-5,000 electric vehicles per month. The company, which on Thursday expanded its electric vehicle portfolio with the launch of a seven seater model XEV 9S, aims the electric range to account for around 25 per cent of its overall volumes by 2027-2028 calendar years.
Tata Power to Build Rs 10,000 Cr Plant in Odisha
Patel Engineering Wins Rs 800 Cr Order
Patel Engineering has secured two projects worth around Rs 800 crore for mining related activities in Chhattisgarh. The company has received letter of intents from Saidax Engineers and Infrastructures. The total project value for both letter of intents combined is Rs 798.19 crore (excluding taxes), Patel Engineering said in a statement.
Wipro To power Odido’s Digital Future
IT services company Wipro Limited has announced a multi-year engagement with Odido Netherlands B.V. to transform its IT landscape and enhance customer experience across their enterprise and consumer segments.
Global Health: Medanta Opens 550-Bed Hospital in Noida
Medanta, one of the largest private multi-speciality tertiary and quaternary care providers operating in the North and East regions of India, formally launched its new state-of-the-art 550-bed super speciality hospital in Noida, marking a major expansion of its presence in the National Capital Region and Uttar Pradesh.
Emcure Pharmaceuticals: GST Raid At Mumbai Office
Emcure Pharmaceuticals has confirmed that a search and seizure/ inspection operation was conducted by the Goods & Service Tax Department, Mumbai, Maharashtra, at the Offices of the company. The operation was commenced on November 24, 2025 and concluded on November 26. Emcure Pharmaceuticals said that it has fully cooperated with the officials throughout the proceedings, providing all necessary documents, clarifications and details as requested.
Zydus Lifesciences Gets Nod For Empagliflozin, Linagliptin Tablets
Zydus Lifesciences Limited has received tentative approval from the United States Food and Drug Administration (USFDA) for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg (USRLD: Glyxambi Tablets, 10 mg/5 mg and 25 mg/5 mg). Empagliflozin and Linagliptin Tablets (10 mg/5 mg and 25 mg/5 mg) in a combination are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate.
(Disclaimer: The above article is meant for informational purposes only, and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money related decisions.)
